Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.45 |
| ▸ | AXL | P30530 | 7/20 | 0.42 |
| ▸ | MET | P08581 | 9/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20478187 | 0.91 | MET (0.36) | BRAFAXLMETKDRRET | |
| SCHEMBL20478190 | 0.91 | BRAF (0.45) | BRAFAXLMETKDRRET | |
| SCHEMBL19987723 | 0.85 | MET (0.42) | BRAFAXLMETKDRRET | |
| SCHEMBL19987755 | 0.85 | MET (0.36) | AXLMETKDRRETKIT | |
| SCHEMBL19987763 | 0.84 | MET (0.44) | AXLMETKDRRETKIT | |
| SCHEMBL19987715 | 0.82 | MET (0.36) | BRAFAXLMETKDRRET | |
| SCHEMBL19987713 | 0.80 | MET (0.42) | BRAFAXLMETKDRRET | |
| SCHEMBL18256819 | 0.80 | AXL (0.61) | BRAFAXLMETKDRRET | |
| SCHEMBL3114486 | 0.80 | MET (0.41) | BRAFAXLMETKDRRET | |
| SCHEMBL19987748 | 0.80 | MET (0.44) | AXLMETKDRRETKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-14 | — | — | US | claimed |
| US-20180244667-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-08-30 | — | — | US | claimed |
| EP-3299369-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-03-28 | — | — | EP | claimed |
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-14 | — | — | US | disclosed |
| US-20180244667-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-08-30 | — | — | US | disclosed |
| EP-3299369-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244667-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | MET, MERTK, DMPK | BRAF 13/4885AXL 212/4885MET 1/4885 |
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | MET, MERTK, DMPK | BRAF 13/4885AXL 212/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.